Ido Wolf

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

David Miles, Joseph Gligorov, Fabrice André et al. · Annals of Oncology · 2021 · 689 citations · Full text

Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor–Positive Breast Cancer

Rinath Jeselsohn, Roman Yelensky, Gilles Buchwalter et al. · Clinical Cancer Research · 2014 · 633 citations · Full text

Cyclophosphamide Triggers Follicle Activation and “Burnout”; AS101 Prevents Follicle Loss and Preserves Fertility

Lital Kalich‐Philosoph, Hadassa Roness, A. Carmely et al. · Science Translational Medicine · 2013 · 545 citations

D538G Mutation in Estrogen Receptor-α: A Novel Mechanism for Acquired Endocrine Resistance in Breast Cancer

Keren Merenbakh-Lamin, Noa Ben-Baruch, Adva Yeheskel et al. · Cancer Research · 2013 · 395 citations

Breast Oncology, Estrogen Receptor-α, Genetics +20

SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer

Guy A. Van Hazel, Volker Heinemann, Navesh Sharma et al. · Journal of Clinical Oncology · 2016 · 339 citations